Durata Therapeutics (DRTX) IPO Prices at $9, Below Expected Range
Tweet Send to a Friend
Durata Therapeutics (Nasdaq: DRTX) priced its initial public offering of 7,500,000 shares of common stock at $9.00 per share, below the expected range of $11-$13. The offering sized was raised from 6,250,000 shares. Shares are scheduled to open on the NASDAQ later today under the ticker symbol "DRTX".
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences are acting as the co-managers for the offering.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences are acting as the co-managers for the offering.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors
- Dan Loeb Builds Massive Stake in Sony (SNE), Wants Entertainment Arm Split
- UPDATE: BofA/Merrill Lynch Upgrades J. C. Penney (JCP) to Neutral
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, Merrill Lynch, Bank of America, RBC Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
